Pharma's lobbying efforts: 10 drugmakers that spent the most so far in 2017

Pharmaceutical and medical device companies have collectively spent $208 million on lobbying efforts so far in 2017, according to data from the Center for Responsive Politics, a nonprofit, nonpartisan research group based in Washington D.C.

The data presented was last updated Oct. 21, 2017.

Here is the amount 10 pharmaceutical organizations spent on lobbying efforts so far this year.

1. Pharmaceutical Research & Manufacturers of America ($19.8 million)

2. Amgen ($8.6 million)

3. Pfizer ($8.5 million)

4. Bayer ($7.05 million)

5. Novartis ($7.04 million)

6. Eli Lilly ($5.55 million)

7. Merck ($5.44 million)

8. Teva Pharmaceuticals ($4.71 million)

9. AbbVie ($4.38 million)

10. Sanofi ($4.19 million)

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars

>